The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The CDE of China's NMPA has granted BTD to Innovent Biologics' IBI343 as a monotherapy treatment for CLDN18.2-positive PDAC ...

In March 2023, the US Food and Drug Administration approved Acadia's Daybue (trofinetide) for treating Rett syndrome in ...

Charles River and Akron Bio have announced the integration of the latter’s CSS liquid cytokines into the former's Cell ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.